Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Share-based Compensation (2016 - 2025)

Lisata Therapeutics' Share-based Compensation history spans 13 years, with the latest figure at $225000.0 for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 64.57% year-over-year to $225000.0; the TTM value through Dec 2025 reached $1.2 million, down 25.83%, while the annual FY2025 figure was $1.2 million, 25.83% down from the prior year.
  • Share-based Compensation reached $225000.0 in Q4 2025 per LSTA's latest filing, down from $232000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $675000.0 in Q1 2023 to a low of $225000.0 in Q4 2025.
  • Average Share-based Compensation over 3 years is $409750.0, with a median of $390500.0 recorded in 2024.
  • Peak YoY movement for Share-based Compensation: skyrocketed 34.25% in 2024, then plummeted 64.57% in 2025.
  • A 3-year view of Share-based Compensation shows it stood at $473000.0 in 2023, then soared by 34.25% to $635000.0 in 2024, then tumbled by 64.57% to $225000.0 in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Share-based Compensation are $225000.0 (Q4 2025), $232000.0 (Q3 2025), and $239000.0 (Q2 2025).